nach oben

Erschienen in:

03.06.2016 | Original Article

Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity

verfasst von: C.-B. Yeh, S.-J. Weng, K.-W. Chang, J. Y.-H. Chan, S.-M. Huang, T.-H. Chu, N.-K. Wei, H.-S. Ma, J.-T. Cheng, K.-H. Ma, T.-H. Chen, J.-F. Shyu

Erschienen in: Osteoporosis International | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

Calcitonin may relieve pain by modulating central serotonin activity. Calcitonin partly reversed the hypersensitivity to pain induced by ovariectomy. This suggests that the anti-nociceptive effects of calcitonin in the treatment of osteoporosis may be mediated by alterations in neural serotonin transporter (SERT) activity.

Introduction

This study used a rat model of osteoporosis to evaluate the role of the cerebral serotonin system in the anti-nociceptive effect of calcitonin, a drug used to treat post-menopausal osteoporosis.

Methods

Osteoporosis was induced in rats by ovariectomy (OVX). Rats were then randomized to the following four groups: sham operation, OVX, OVX plus calcitonin, or OVX plus alendronate.

Results

OVX led to alterations in bone micro-architecture; alendronate strongly reversed this effect, and calcitonin moderately reversed this effect. OVX increased hyperalgesia (determined as the time for hind paw withdrawal from a heat source); calcitonin reduced this effect, but alendronate had no effect. OVX increased the expression of c-Fos (a neuronal marker of pain) in the thalamus; calcitonin strongly reversed this effect, and alendronate moderately reversed this effect. OVX also reduced SERT but increased 5-HT1A receptor expression and activity; calcitonin aggravated this effect, but alendronate had no effect on recovery of SERT/5-HT1A activity and expression.

Conclusions

Our study of a rat model of osteoporosis suggests that OVX-induced enhancement of the serotonergic system may protect against hyperalgesia. However, the anti-nociceptive effects of calcitonin in osteoporosis may be mediated by decreased neural SERT activity and increased activation of 5-HT1 receptors in the thalamus.

Diab DL, Watts NB (2013) Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 20:501–509CrossRefPubMed

Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170CrossRefPubMed

Karsdal MA, Henriksen K, Arnold M, Christiansen C (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22:137–144CrossRefPubMed

Takayama B, Kikuchi S, Konno S, Sekiguchi M (2008) An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats. BMC Musculoskelet Disord 9:164CrossRefPubMedPubMedCentral

Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H (2011) Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int 22:2735–2742CrossRefPubMed

Fujita T, Ohue M, Nakajima M, Fujii Y, Miyauchi A, Takagi Y (2011) Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. J Bone Miner Metab 29:588–597CrossRefPubMed

Gennari C (2002) Analgesic effect of calcitonin in osteoporosis. Bone 30:67S–70SCrossRefPubMed

Lyritis GP, Trovas G (2002) Analgesic effects of calcitonin. Bone 30:71S–74SCrossRefPubMed

Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D (2012) Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 23:17–38CrossRefPubMed

10.

Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281–1290CrossRefPubMed

11.

Gobelet C, Meier JL, Schaffner W, Bischof-Delaloye A, Gerster JC, Burckhardt P (1986) Calcitonin and reflex sympathetic dystrophy syndrome. Clin Rheumatol 5:382–388CrossRefPubMed

12.

Hamamci N, Dursun E, Ural C, Cakci A (1996) Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Br J Clin Pract 50:373–375PubMed

13.

Matayoshi S, Shimodozono M, Hirata Y, Ueda T, Horio S, Kawahira K (2009) Use of calcitonin to prevent complex regional pain syndrome type I in severe hemiplegic patients after stroke. Disabil Rehabil 31:1773–1779CrossRefPubMed

14.

Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ (2001) Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manag 21:511–526CrossRef

15.

Quatraro A, Minei A, De Rosa N, Giugliano D (1992) Calcitonin in painful diabetic neuropathy. Lancet 339:746–747CrossRefPubMed

16.

Visser EJ, Kwei PL (2006) Salmon calcitonin in the treatment of post herpetic neuralgia. Anaesth Intensive Care 34:668–671PubMed

17.

Zieleniewski W (1990) Calcitonin nasal spray for painful diabetic neuropathy. Lancet 336:449CrossRefPubMed

18.

Azria M (2002) Possible mechanisms of the analgesic action of calcitonin. Bone 30:80S–83SCrossRefPubMed

19.

Davey RA, Findlay DM (2013) Calcitonin: physiology or fantasy? J Bone Miner Res 28:973–979CrossRefPubMed

20.

Guidobono F, Netti C, Sibilia V, Olgiati VR, Pecile A (1985) Role of catecholamines in calcitonin-induced analgesia. Pharmacology 31:342–348CrossRefPubMed

21.

Maeda Y, Yamada K, Hasegawa T, Nabeshima T (1995) Neuronal mechanism of the inhibitory effect of calcitonin on N-methyl-D-aspartate-induced aversive behavior. Eur J Pharmacol 275:163–170CrossRefPubMed

22.

Meisenberg G, Simmons WH (1983) Minireview. Peptides and the blood–brain barrier. Life Sci 32:2611–23CrossRefPubMed

23.

Pecile A (1992) Calcitonin and relief of pain. Bone Miner 16:187–189CrossRefPubMed

24.

Sibilia VF, Pagani N, Lattuada D, Rapetti F, Guidobono NC (2000) Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. Brain Res 854:79–84CrossRefPubMed

25.

Yoshimura M (2000) Analgesic mechanism of calcitonin. J Bone Miner Metab 18:230–233CrossRefPubMed

26.

Viguier F, Michot B, Hamon M, Bourgoin S (2013) Multiple roles of serotonin in pain control mechanisms—implications of 5-HT(7) and other 5-HT receptor types. Eur J Pharmacol 716:8–16CrossRefPubMed

27.

Craft RM (2007) Modulation of pain by estrogens. Pain 132(Suppl 1):S3–12CrossRefPubMed

28.

Martin VT (2009) Ovarian hormones and pain response: a review of clinical and basic science studies. Gend Med 6(Suppl 2):168–192CrossRefPubMed

29.

Ito A, Takeda M, Yoshimura T, Komatsu T, Ohno T, Kuriyama H, Matsuda A, Yoshimura M (2012) Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors. Mol Pain 8:42CrossRefPubMedPubMedCentral

30.

Kharode YP, Sharp MC, Bodine PV (2008) Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol 455:111–124CrossRefPubMed

31.

Zheng XF, Li B, Zhang YH, Yang YH, Meng XY, Jiang SD, Jiang LS (2013) Blockade of substance P receptor attenuates osteoporotic pain, but not bone loss, in ovariectomized mice. Menopause 20:1074–1083CrossRefPubMed

32.

Egermann M, Goldhahn J, Schneider E (2005) Animal models for fracture treatment in osteoporosis. Osteoporos Int 16(Suppl 2):S129–138CrossRefPubMed

33.

Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA (2008) The laboratory rat as an animal model for osteoporosis research. Comp Med 58:424–430PubMedPubMedCentral

34.

Kuo YJ, Tsuang FY, Sun JS, Lin CH, Chen CH, Li JY, Huang YC, Chen WY, Yeh CB, Shyu JF (2012) Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis. PLoS One 7:e40272CrossRefPubMedPubMedCentral

35.

Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283–8CrossRefPubMed

36.

Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R (1993) The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain 54:43–50CrossRefPubMed

37.

Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77–88CrossRefPubMed

38.

Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, Burlington, MA, USA, p 208

39.

Muller R, Van Campenhout H, Van Damme B, Van Der Perre G, Dequeker J, Hildebrand T, Ruegsegger P (1998) Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 23:59–66CrossRefPubMed

40.

Abate G, Taormina F, Brillante C, Fraccalaglio L (1994) The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis. Minerva Med 85:253–259PubMed

41.

Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367:2416–2425CrossRefPubMedPubMedCentral

42.

Hirsch PF, Lester GE, Talmage RV (2001) Calcitonin, an enigmatic hormone: does it have a function? J Musculoskelet Nueronal Interact 1:299–305

43.

Overman RA, Borse M, Gourlay ML (2013) Salmon calcitonin use and associated cancer risk. Ann Pharmacother 47:1675–1684CrossRefPubMed

44.

Purdue BW, Tilakaratne N, Sexton PM (2002) Molecular pharmacology of the calcitonin receptor. Recept Channels 8:243–255CrossRefPubMed

Titel: Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity
verfasst von: C.-B. Yeh
S.-J. Weng
K.-W. Chang
J. Y.-H. Chan
S.-M. Huang
T.-H. Chu
N.-K. Wei
H.-S. Ma
J.-T. Cheng
K.-H. Ma
T.-H. Chen
J.-F. Shyu
Publikationsdatum: 03.06.2016
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 11/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3652-1

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity

Abstract

Summary

Introduction

Methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Summary

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Measurements of skeletal muscle mass and power are positively related to a Mediterranean dietary pattern in women

Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH)

Selective protein depletion impairs bone growth and causes liver fatty infiltration in female rats: prevention by Spirulina alga

Considerations concerning the definition of sarcopenia: response to comments

Skeletal phenotypes in adult patients with osteogenesis imperfecta—correlations with COL1A1/COL1A2 genotype and collagen structure

Systemic markers of microvascular disease and bone mineral density in older adults

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie